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Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND), and N95% of fa-
milial and sporadic cases involve the deposition of insoluble aggregated, phosphorylated and cleaved TDP-43
protein. Accumulating clinical and biological evidence now indicates that ALS bears a number of similarities to
the prion diseases, with TDP-43 acting as a misfolded ‘prion-like’ protein demonstrating similar underlying
pathobiology. Here we systematically address the hypothesis that ALS is a prion-like disorder. First we demon-
strate that TDP-43 demonstrates seeded polymerisation in vitro directly from both ALS brain and spinal cord.
We next show that the seeding of TDP-43 results in the formation of characteristic insoluble, aggregated, and
phosphorylated TDP-43 pathology that directly recapitulates the morphological diversity of TDP-43 inclusions
detected in ALS patient CNS tissue.We next demonstrate that this reaction can be serially propagated to produce
increasing amounts of phosphorylated TDP-43 pathology, and that aggregates can spread from cell to cell in an
analogous fashion to that seen in the prion diseases. Finally, we reproduced our ﬁndings in a murinemotor neu-
ron-like cell line (NSC-34), where the seeding of TDP-43 induces the formation of TDP-43 oligomers and reduced
cell viability. These ﬁndings may guide therapeutic strategies in this rapidly progressive and invariably fatal
disease.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive, age-related,
fatal neurodegenerative disorder that predominantly causes the death
of upper and lower motor neurons. This results in muscle spasticity,
weakness, atrophy and eventual paralysis, where death is usually
caused by degeneration of motor neurons innervating respiratory mus-
culature (Wijesekera and Leigh, 2009). Accumulating evidence impli-
cates a role for prion-like features in a number of neurodegenerative
disorders including ALS (Frost and Diamond, 2010; Jucker and Walker,
2011; Polymenidou and Cleveland, 2011). Clinically, ALS demonstrates
similarities to the prion diseases with a characteristic spreading of de-
generation within the CNS. In ALS, this is often well recognised by a
clear focal onset of clinical features which then spreads to neighbouring
sites indicating disease propagation. (Ravits, 2014; Ravits et al., 2007;
Ravits and La Spada, 2009). Indeed, pathological examination corrobo-
rates clinical symptom spread, with a site of severe degeneration and
cell loss from a focal onset in the neuraxis that diminishes further
from the onset site (Ravits et al., 2007a, 2007b).
The prion diseases are the prototypic protein misfolding disorders
characterised by the accumulation of self propagating polymers of
misfolded PrP. Cell to cell propagation of these misfolded protein poly-
mers culminates in dissemination throughout the central nervous sys-
tem (CNS). Different misfolded PrP subtypes, referred to as strains
(Collinge et al., 1996), can lead to variation in both regional distribution
and clinical features (Collinge and Clarke, 2007). It is currently not
known how prions cause toxicity, however one hypothesis states that
they may do so through the development of toxic oligomers
(Sandberg et al., 2014; Sandberg et al., 2011) similar to that proposed
with beta amyloid in Alzheimer's disease (Haass and Selkoe, 2007;
Umeda et al., 2015; Wilcox et al., 2011). Indeed, this has led to an
emerging theme among other neurodegenerative disease-related pro-
teins including α-synuclein (Winner et al., 2011), Tau
(Lasagna-Reeves et al., 2011; Tian et al., 2013), and now TDP-43 (Fang
et al., 2014).
The pathological hallmark of ALS is the deposition of ubiquitinated
aggregated proteins which, in N95% of all cases, contain TDP-43 (Arai
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et al., 2006; Neumann et al., 2006). TDP-43 is coded for by the TARDBP
gene on chromosome 1; it is a ubiquitously expressed and well con-
served 414 amino acid protein. TDP-43 consists of an N-terminal do-
main, two RNA binding domains, a glycine-rich C-terminal and a
bipartite nuclear export and localization sequence. TDP-43 is a multi-
functional RNA binding protein normally localised in the nucleus, how-
ever in the majority of ALS cases it is mislocalised from the nucleus to
the cytoplasm, where it becomes insoluble, hyperphosphorylated and
cleaved (Arai et al., 2006; Hasegawa et al., 2008; Neumann et al.,
2006). These pathological insights, taken together with the discovery
that mutations in TDP-43 can cause ALS (Daoud et al., 2009; Kabashi
et al., 2008; Sreedharan et al., 2008) and FTLD (Benajiba et al., 2009;
Borroni et al., 2009), implicate TDP-43 as a pivotal pathogenic factor
both in ALS and FTLD, with these forming an ALS/FTLD disease continu-
um (Janssens and Van Broeckhoven, 2013).
TDP-43 demonstrates signiﬁcant prion-like features (reviewed in
Smethurst et al., 2015). Recombinant TDP-43 can form aggregates via
a proposed templated seeding reaction in cell culture (Furukawa et al.,
2011), and TDP-43 aggregates from ALS and FTLD brains can also seed
characteristic TDP-43 pathology in cell culture (Nonaka et al., 2013).
TDP-43 seeded directly fromhumanCNS tissue induces cellular toxicity,
proteasome dysfunction, and cell-to-cell propagation (Nonaka et al.,
2013),whilst demonstrating resistance to heat, denaturation and prote-
ases. Pathological reports of phosphorylated TDP-43 (pTDP-43) in ALS
post-mortem brain (Brettschneider et al., 2013) and spinal cord
(Brettschneider et al., 2014) suggest that TDP-43 pathology could
spread via axonal trajectories and synaptic connections as well as non-
contiguous spread. Further, the majority of pathogenic ALS-causing
TARDBP mutations occur in the C-terminus of TDP-43 (Pesiridis et al.,
2009), which is involved in protein-protein interactions (Kuo et al.,
2009) and protein localisation (Nonaka et al., 2009b). The C-terminus
has been termed a ‘prion-like’ domain as it contains a glutamine and
asparganine (Q/N) rich region which regulates its self association, ag-
gregation and amyloid forming potential (Fuentealba et al., 2010;
Saini and Chauhan, 2014, 2011).
Against this background, it is possible that the prion-like behaviour
of TDP-43 is a keymechanistic feature in ALS. Here,we use an integrated
approach: isolating protein extracts from human post-mortem tissue
and systematically transfecting them into different in vitro cellular
model systems to investigate TDP-43 seeding potential and characteris-
tics. We demonstrate that pathological pTDP-43 aggregates can be ex-
tracted from both ALS brain and spinal cord tissue, the latter arguably
representing the more pathologically relevant tissue with respect to
ALS, and form a seeded polymerisation in cell culture. These pTDP-43
assemblies can mislocalise endogenous TDP-43 from the nucleus to
the cytoplasmwhere it becomes insoluble and aggregated; thus recapit-
ulating the pathological hallmark of ALS, including a diverse array of
established TDP-43 inclusion morphologies. In turn, we have demon-
strated that this reaction can be serially passaged from cells containing
pTDP-43 aggregates, and further increasing the amount of pTDP-43 pa-
thology upon serial passage.We also demonstrate that these aggregates
can spread from cell to cell in a prion-likemanner. Finally, we show this
seeding reaction in a motor neuron-like cell line that demonstrates for-
mation of TDP-43 oligomers and signiﬁcantly reduced cell viability.
2. Materials and methods
2.1. CNS tissue homogenate extractions
Post-mortem frozen CNS tissue samples were obtained from a num-
ber of sources including theNeuroResource tissue bank (UCL Institute of
Neurology, London), the London Neurodegenerative Diseases Brain
Bank (King's College, London) and the Queen Square Brain Bank for
Neurological Disorders (UCL Institute of Neurology, London). All tissue
samples were obtained with informed consent and under Research
Ethics Commitee and Human Tissue Authority (HTA) regulations. ALS
cases were clinically, electrophysiologically and pathologically deﬁnite
cases. All brains were pathologically conﬁrmed to have TDP-43 positive
neuronal cytoplasmic inclusions.
To prepare phosphate-buffered saline (PBS) tissue extractions, each
block of snap-frozen tissuewas homogenised in 9 x tissuewetweight of
PBS using a probe sonicator and 750ul aliquots were frozen at−80 °C.
For sarkosyl insoluble urea soluble fractions, CNS tissue was
homogenised and extracted as described previously (Arai et al., 2006;
Hasegawa et al., 2008) butwith somemodiﬁcations. For each extraction
we took 500 μl of 10% tissue homogenate and added an equal amount of
2× extraction buffer A (BA: 10 mM Tris, 0.8 M NaCl, 10% sucrose, 1 mM
EGTA, pH 7.5) with 2% triton X-100, 2× protease (Roche, Cat. no.
05892970001) and phosphatase inhibitor cocktail tablets (Roche, Cat.
no. 04906837001). This was incubated for 30 min at 37 °C and
ultracentrifuged (100,000 ×g, 30 min, 4 °C). The supernatant was
discarded, and the pellet was brieﬂy sonicated in the starting volume
(500 μl) of 1× BA containing 1% sarkosyl (Sigma, Cat. no. L9150) with
1× protease and phosphatase inhibitors, then incubated at 37 °C for
30 min. The sample produced was ultracentrifuged (100,000 ×g,
30min, 23 °C) and the supernatantwas discarded. The pelletwas brieﬂy
sonicated in 200 μl of 1 x BA containing 1% CHAPS (Sigma, Cat. no.
C9246) with the protease and phosphatase inhibitors, and
ultracentrifuged for 20 min at 25 °C. The supernatant was removed
and discarded and the pellet was resuspended 50 μl of 8 M urea
(pH 7.5).
For the TDP-43 seeding the homogenate was extracted using the tis-
sue homogenisation buffer (HB)made at 2× concentration (HB: 10mM
Tris- HCl, pH 7.5 containing 0.8 M NaCl, 1 mM EGTA, 1 mM dithiothrei-
tol) containing a 2% sarkosyl detergent and protease and phosphatase
inhibitors. Then 750 μl of this buffer was added to the homogenates to
make a ﬁnal of 1× HB with 1% sarkosyl. These samples were incubated
at 37 °C for 30 min and centrifuged (12,000 ×g, 10 min). The superna-
tant was ultracentrifuged (50,000 ×g, 10 min, room temperature). The
pellet was washed in sterile PBS, sonicated and re-ultracentrifuged
(100,000 ×g, 20 min, room temperature). The ﬁnal pellet was resus-
pended by sonication in 25 μl of sterile PBS per pellet. In order to achieve
workable amounts of TDP-43 seeding, 4 to 6 aliquots of homogenate
were extracted per CNS region.
2.2. TDP-43 constructs
The wild type FLAG tagged TDP-43 gene was previously cloned into
the pFLAG-CMV2 vectorwhichwas a kind gift fromBurratti and Barralle
(Ayala et al., 2008). The full length wild type TDP-43 was transformed
into E. coli to propagate the plasmid. For this 50-100 μl of High Efﬁciency
JM109 or HB101 E. coli cells (thawed slowly on ice) and 5 μl–10 μl of li-
gation reaction (i.e. 10% of the cell volume) were mixed and incubated
on ice for 15 min then “heat shocked” for 30 s in a 42 °C heating block
and returned to the ice for 10 min. After the addition of 500 μl–1 ml of
LB-broth (for low or high copy number vectors respectively), the cells
were incubated at 37 °C for 1 h with horizontal agitation at 150 rpm.
Gentle centrifugation at 3000 ×g formed a cell pellet which, after re-
moval of the supernatant, was re-suspended in 100 μl of LB-broth. The
full cell suspensionwas spread on an LB-agar plate containing an appro-
priate selection antibiotic and incubated overnight at 37 °C.
Single, well-deﬁned colonies were individually picked and cultured
in 3 ml of L-broth containing the selection antibiotic. Following over-
night incubation at 37 °C with vigorous horizontal agitation at
250 rpm, the cultured cells were harvested by centrifugation at
17,000 ×g. Cloned plasmid DNA was extracted from the bacterial cells
using the QIAquick Spin Miniprep kit (Cat. no. 12,123, QIAGEN) accord-
ing to themanufacturer's protocol. For larger quantities of DNA the bac-
teria were grown in 250ml of LB broth and incubated overnight at 37 °C
with agitation at 250 rpm. After this, the QIAGENmaxi prep kit (Cat. no.
12362, QIAGEN) was used to extract and purify the DNA used for trans-
fection according to the manufacturer's protocol. Final conﬁrmation of
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cloned plasmid constructs was achieved by sequencing. All DNA se-
quencing was outsourced to a service provider, Source BioScience Ltd.
2.3. Cell culture
Human embryonic kidney (HEK) 293 and Neuroblastoma spinal
cord 34 (NSC-34) cells were cultured in DMEM with high glucose and
5 mM Glutamine containing 10% FBS. Cells were grown at 37 °C and
5% CO2 up to 80–90% conﬂuency then were passaged at 1 in 10 and
grown for up to aweekwhere themediumwas changed every 2–3 days.
2.4. Transfection of plasmids and proteins to cell culture
Cells were either grown in 24 well plates for IF staining or 6 well
plates for western blotting. In each case transfection of plasmids was
performed using Lipofectamine 3000 (Invitrogen) according to the
manufacturer's instructions. In brief, we used DMEM with no FBS as
transfection media and added 0.75 μl of lipofectamine and 1 μl of
P3000 reagent with 0.5 μg of plasmid DNA per 1 well of a 24 well
plate, and 3.75 μl of lipofectamine with 5 μl of P3000 reagent and
2.5 μg of plasmid DNA per 1 well of a 6 well plate.
To inoculate the insoluble TDP-43 protein seed from theALS CNSho-
mogenates, the transfection process was the same as above but with
5 μg of protein in replacement of the DNA. Both plasmids and TDP-43
seeds were co-transfected and were incubated for a maximum of
3 days post transfection. For IF analysis the cells were ﬁxed in 4% PFA.
For western blotting and serial propagation the cells were harvested
by trypsinising in 0.25% Trypsin with EDTA and centrifuged at
2000 rpm for 5 min. Themedia was discarded and the pellet was resus-
pended and sonicated in 50 μl of TS buffer (150 mM Tris HCl, 50 mM
NaCl, 5mMEDTA, and 5mMEGTA) containing 1% sarkosyl andprotease
and phosphatase inhibitors. The samples were sonicated and incubated
at 37 °C for 30 min. The samples were ultra-centrifuged at 290,000 ×g
for 20 min at room temperature. The supernatant was used as the
sarkosyl soluble (SS) fraction and the pelletwas resuspended by sonica-
tion in either 25 μl of 8 M urea per 1 well of a 6 well plate for western
blotting, or 25 μl of sterile PBS per 1well of a 6 well plate for serial prop-
agation. A BCA assay was performed on both fractions, and 10–20 μg of
proteinwas loaded on a gel for blotting and 5 μg of protein from the PBS
suspended pellet was transfected to the next culture.
2.5. TDP-43 propagation
For serial propagation 5 μg of the sterile PBS fractions of the treated
cells were co transfected with the FLWT TDP-43 plasmid and incubated
for 3 days and harvested as before where half of the pellet was used for
western blotting and the other half was resuspended in sterile PBS for
further propagation.
For aggregate spreading, HEK cells were grown to ~60–70%
conﬂuency in 24 well plates and either seeded with the FL WT and
ALS inocula or transfected with GFP. After 3 days of incubation both
wells were trypsinised in 0.25% trypsin for 5 min and spun down at
2000 rpm for 5 min. Both populations of cells were mixed together in
a 1:1 ratio and plated onto a 22 mm diameter coverslip and incubated
for a further 3 days. Cells were ﬁxed in 4% paraformaldehye (PFA) for
immunocytochemical analysis.
2.6. Immunocytochemistry
Cells were gently washed with PBS and ﬁxed for 15 min in 4% PFA
then gently washed again in PBS and permeabilised with 0.5% triton
X-100 in PBS for 10–15 min. The coverslips were blocked in 5% BSA
for 30 min and stained with either polyclonal rabbit anti-TDP-43
(1:500) (Proteintech, Cat. no. 10782-2-AP), monoclonal mouse anti-
TDP-43 (1:500) (Proteintech, Cat. no. 60019-2-Ig), polyclonal anti-rab-
bit phospho-TDP-43 (pS409/410-1) (1:500) (CosmoBio, Cat. no. TIP-
PTD-P01), polyclonal anti-rabbit TDP-O (1:500) (a gift from Dr. Yun
Ru Chen), monoclonal anti-mouse FLAG M2 (Sigma, Cat. no. F3165) in
5% BSA for 2 h at room temperature. Cells were gently washed in PBS
3 times and incubated with ﬂuorescent secondary anti-rabbit Alexa-
Fluor 488 and anti-mouse or anti-rabbit Alexa-Fluor 568 antibodies
(1:2000) (Invitrogen) in 5% BSA for 1 h and washed again as before.
They were mounted with DAPI Fluoromount G onto slides, allowed to
dry and visualised with a Zeiss 700 confocal microscope.
2.7. Immunoblotting
Samples weremeasured for protein concentration using a BCA assay
(Bio\\Rad) and either 10 or 20 μg of protein was loaded on to a gel.
These samples were added to an equal amount of working SDS solution
with β-mercaptoethanol and boiled at 100 °C for 5 min. The samples
were vortexed and centrifuged at 14,800 rpm for 1 min. Equal amounts
of protein fromeach samplewere loaded on to a 15well 16% tris glycine
SDS PAGE gels (Cat. No. EC64985BOX, Invitrogen) and run at 200 V for
70 min. Gels were transferred and blotted onto nitrocellulose mem-
branes (Cat. No. 10401196, Protran) for either 2 h at 35 V or 15 V at
4 °C overnight. Membranes were then blocked in 5% non-fat milk in
PBS for 30 min and probed with either anti-rabbit polyclonal pTDP-43
(pS409/410) (Proteintech, Cat. No. 223091-AP) (1:1000), monoclonal
anti-mouse FLAG M2 (Sigma, Cat. no. F3165) or mouse monoclonal β-
actin antibody Clone AC-15 (1:20,000) (Cat. no. A1978, Invitrogen), in
1% non-fat milk in PBS + 0.1% tween (PBST). Blots were washed 3
times for 5min each in PBST and probedwith secondary ﬂuorescent an-
tibodies: goat anti rabbit IgG antibody IRDye800 (green) (Cat. no. 611-
132-122, Tebu-bio) (1:10,000), Alexa Fluor 700 goat anti mouse IgG
(red) (Cat. no. A-21036, Invitrogen) (1:10,000) in 1% Non-fat milk in
PBST. Blots were washed again 3 times for 5 min in PBST and washed
once in PBS, then visualised with an Odyssey scanner.
2.8. Cellular toxicity assays
For the assessment of cellular viability the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl- 2H-tetrazolium bromide (MTT) assay was performed
usingMTT salt (Sigma, Cat. no. M5655) resuspended at 1mg/ml in ster-
ilewater. Cellswere plated out in 96well plates at 500 cells perwell and
co-transfected as previously described, then on day 3 20 μl of the 1 mg/
mlMTT solution was added to each well and left to incubate at 37 °C for
2–4 h Themedia from each well was decanted and replaced with 100 μl
of dimethyl sulfoxide (DMSO) until all the purple formazanproductwas
dissolved and the plate was read at 570 nm. Absorbance readings were
taken as a percentage of the mean value of non-treated cells.
2.9. Densitometry and statistical analysis
Densitometry analysis was performed using the raw data on the in-
built Odyssey densitometry software and statistical analysis was carried
out using Prism 4 software. An unpaired two tailed student's t-test was
usedwhen comparing between two individual groups cases to generate
a statistical p value. A one way ANOVA was used when comparing 2 or
more groups with a post hoc Tukey test to compare all groups. Any p
value below 0.05 was considered to be statistically signiﬁcant
(*p b 0.05, **p b 0.01, ***p b 0.001).
3. Results
3.1. Seeding and aggregation of TDP-43 from ALS CNS tissue
To test the hypothesis that a TDP-43 seeding reaction can be initiat-
ed from both brain and spinal cord ALS post-mortem tissue into cell cul-
ture, we extracted protein lysates from ALS, pathologically conﬁrmed,
brain and spinal cord samples. On repeated testing, only samples con-
taining phosphorylated TDP-43 on Western blotting (WB) were able
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to seed TDP-43 aggregation. Therefore, samples exhibiting robust phos-
phorylated TDP-43 (pS409/410 or ‘pTDP-43’) pathology were selected
for further experiments (Fig. 1A and Table S1). In order to test the con-
ditions necessary to seed TDP-43 in cell culture, we transfected 5 μg of
protein extract from control or ALS cases into HEK293 cells which
were either unmodiﬁed or expressed a full length wild type TDP-43
FLAG-tagged construct. Immunoﬂuorescence (IF) labelling of cells or
western blot (WB) analysis on the sarkosyl insoluble (SI) cell fractions
was next conducted (soluble fractions demonstrated no changes or de-
velopment of pTDP-43 pathology; data not shown). Sarkosyl insoluble
extracted samples from normal control brain, spinal cord and
Parkinson's disease brain were used as healthy and disease controls re-
spectively (Fig. 1A). Transfection of pTDP-43 extracts from ALS brain or
spinal cord alone into HEK cells did not reveal any pTDP-43 pathology
after 3 days of incubation on a WB or immunocytochemistry (ICC)
(Fig. 1B and E). This demonstrates two points; ﬁrstly that the ALS inoc-
ula alone is not enough to induce the formation of pTDP-43 inclusions in
the absence of an overexpressed TDP-43 construct, and secondly, that
any signal observed was not simply due to the presence of residual
starting inocula material. In contrast, co-transfection of HEK cells with
the full length WT construct (FL WT) and ALS brain or spinal cord sam-
ples, revealed pathological pTDP-43 bands onWB (Fig. 1B) after 3 days.
The quantiﬁcation of these bands demonstrates a signiﬁcant increase in
the 46 kDa band of pTDP-43 at 3 days post incubation with ALS tempo-
ral cortex (TCX) and motor cortex (MC) samples (***p b 0.001, n= 3)
compared to the cells expressing the FLWT and FLWT seededwith con-
trol inocula. However, whilst the signal from the ALS spinal cord (SC)
demonstrates an increase, this does not reach signiﬁcance here (Fig.
1C). In this experimental condition alone, we observed the formation
of numerous pTDP-43 positive cytoplasmic aggregates, which co-local-
ised with the FLWT TDP-43, and depleted the nucleus of FLWT TDP-43
(Fig. 1E). This is reminiscent of TDP-43 pathology observed in CNS tissue
from patients with ALS and FTLD. Indeed, the pTDP-43 inclusions
formed from inoculationwithALS brain tissuesmore commonly formed
the 25 kDa pTDP-43 bands, compared to the spinal cord samples which
only formed the 45 kDa pTDP-43 band (appears as ~46 kDa due to the
added 1 kDa FLAG), which is in agreement with previous observations
of enrichment of the 25 kDa C-terminal fragments (CTFs) in ALS brain
rather than spinal cord tissue (Igaz et al., 2008).
To ensure that the formation of pTDP-43 pathology observed from
these experiments was a result of de novo propagation, and not persis-
tence of the pTDP-43 from the transfected ALS inocula, a time-course
seeding experiment was conducted over 3 days (Fig. 1C). These data
demonstrate an increasing presence of pTDP-43 bands over 1, 2 and
3 days. Indeed, the densitometry of the pTDP-43 46 kDa band demon-
strates signiﬁcant increases between day 1 and 2 (***p b 0.001, n= 5)
and day 2 and 3 (**p b 0.01, n=5) (Fig. 1E). This is consistentwith gen-
uine de novo aggregation (Fig. 1C). Furthermore, in theALSmotor cortex
treated cells, the 46 kDa band forms before the 25 kDa band from day 2
to 3 suggesting that the cleavage of TDP-43 occurs post phosphorylation
(Fig. 1C), and the full length protein becomes phosphorylated ﬁrst.
Noting that the TDP-43 seeding reaction is more efﬁcient in cells ex-
pressing the full length TDP-43 wild type construct, we hypothesized
that TDP-43 overexpression in these cells increases reaction efﬁciency
(by increasing the substrate concentration). We measured the levels
of sarkosyl soluble (SS) and insoluble (SI) TDP-43 on blots with densi-
tometry, and conﬁrmed a signiﬁcantly increased levels of total TDP-43
in both SS and SI fractions in cells expressing the FL WT plasmid (‘+’)
compared to the cells without the plasmid (‘–‘) (Fig. 1D; ***p b 0.001).
3.2. Morphological diversity of seeded TDP-43 inclusions
TDP-43 inclusions in the brain and spinal cord of patients with ALS
can have varying morphologies including pre-inclusions (wispy and
granular), skein, dash, dot, and round inclusions (Mori et al., 2008)
(Fig. 2A). From our immunoﬂuoresence staining experiments of cells
seeded with TDP-43 from ALS brain or spinal cord, we conﬁrmed that
this full spectrum of morphological inclusion types are faithfully reca-
pitulated in cell culture, and co-localise with FLAG tagged and endoge-
nous TDP-43 (Figs. 2B and S1). Indeed, different morphologies can be
present in close proximity to others (Fig. 2B, Dot/Dash/Round) suggest-
ing a high degree of heterogeneity of inclusions occurring within the
same sample. The co-localisation of the FLAG tagged TDP-43 in the ag-
gregates is highly suggestive of a de novo seeded aggregation reaction.
When the cells were stained for total TDP-43 the endogenous TDP-43
can also be seen to be removed from the cytoplasm and recruited in
these aggregates alongside the FLAG tagged construct (Fig. S1N).
These cells also demonstrate characteristic mislocalisation of TDP-43
(FLAG tagged and endogenous) from the nucleus to the cytoplasm
(Fig. 2B) as seen in patients with ALS and FTLD. However, some inclu-
sions are also formedwith the FLWT TDP-43 still present in the nucleus
(Figs. 2B and S1A), suggestive of an incomplete mislocalisation and ag-
gregation process.
Additionally, the presence of diffuse cytoplasmic staining in the form
of granular ‘pre-inclusions’ (Fig. 2B) suggests that some of these aggre-
gates may still be in the maturation stage (Mori et al., 2008). Here we
demonstrate the formation of two distinct types of diffuse cytoplasmic
deposits: linear wisps and punctate granules, which occur in cells ex-
pressing the FLWT TDP-43 plasmid and treated with ALS inocula. Addi-
tionally, some round pTDP-43 inclusions can contain radiating spiculae
in their margin, or fringes of thread like structures which are typical of
inclusions observed in patients with ALS (Lowe et al., 1988;
Murayama et al., 1990; Sasaki and Maruyama, 1991). These particular
morphological characteristics can also be observed in the pTDP-43 in-
clusions formed here (Fig. 2B).
3.3. Serial passage of TDP-43 pathology
Misfolded prion proteins representing different prion strains can be
serially passaged in vitro and in vivo to maintain the strain speciﬁc con-
formational protein structures (Collinge and Clarke, 2007). We next in-
vestigated if we were able replicate this in cell culture by extracting the
sarkosyl insoluble fraction from cells transfectedwith the FLWT TDP-43
plus ALS tissue extracted pTDP-43 (ALS TCX), and then re-transfecting
of 5 μg of the cell extract (SK) into naive cells expressing FL WT TDP-
43 (Fig. 3). We conﬁrmed a pathological TDP-43 seeding reaction in
the new cells using western blot and immunoﬂuorescent staining (Fig.
3A andB). Despite ensuring that equal quantities of proteinwere loaded
on the initial seeding reaction and passage, there was a signiﬁcant in-
crease in the amount of pTDP-43 46 kDa band on western blotting
(***p b 0.001; Fig. 3C) in the cells exposed to passaged extract compared
to cells exposed to the ALS TCX inocula. In order to determine if this re-
sult was simply due to increased amounts of seed in the inocula, or an
enhanced seeding capacity, we corrected the levels of pTDP-43 bands
with β-actin to determine the total levels of pTDP-43 in each treatment.
Cells expressing the FLWT TDP-43 treated with ALS TCX inocula, in fact
demonstrated lower levels of the pTDP-4325kDa band compared to the
original ALS TCX inocula. However, after subsequent passage of inocula
prepared from these cells onto naive cells expressing FL WT TDP-43,
there was a signiﬁcant increase in the pTDP-43 25 kDa bands
(*p b 0.05; Fig. 3D). This increase in pTDP-43 levels following passage
may therefore be consistent with amore efﬁcient propagation, reminis-
cent of the adaption seen in prion passage into a new host.
3.4. TDP-43 aggregate spread
Previous publications (Ding et al., 2015; Nonaka et al., 2013) have
demonstrated that TDP-43 inclusions can spread from cell to cell in a
prion-like manner although themechanism of how this occurs remains
unclear. In order to conﬁrm theseﬁndings,we co-cultured cells contain-
ingpTDP-43 inclusions andmixed them in a 1:1 ratiowith cells express-
ing GFP. The cells expressing GFP were used as markers of ‘acceptor
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cells’ or naïve cells for the potential uptake of aggregates in the propaga-
tion process. These cells were then further cultured for 3 days and im-
munostained for pTDP-43 (pS409/410) and analysed for the presence
of pTDP-43 aggregates within cells expressing GFP. Fig. 4A and B are
representative images of cells containing pathological cytoplasmic
pTDP-43 inclusions which also express GFP. The 3D reconstruction of
these images show the presence of the cytoplasmic inclusion in all
axes (Fig. 4A and B), and the intensity distribution proﬁles show the
presence of the pTDP-43 inclusion (red line) with GFP (green line)
and its cytoplasmic localization (nucleus is the blue line) (Fig. 4C and
D). These data indicate that the inclusions of pTDP-43 from the original
seeded cells are now present in the acceptor cells, which further sup-
ports the occurrence of pTDP-43 aggregate spread from cell to cell.
After 3 days the number of cells expressing GFP and pTDP-43 inclu-
sions were low, indicating that either the aggregate spreadingmay be a
slow process, may be rate limited by the seed concentration, or that the
Fig. 2. Morphological diversity of pTDP-43 inclusions seeded into HEK cells. A) Diagrammatic illustration of different morphological types of neuronal cytoplasmic inclusions seen in
motor neuron cell bodies from patients with ALS. B)Differentmorphological types of inclusions observed upon seeding of pathological pTDP-43 (green) from ALS patient CNS tissue onto
cells expressing FLAG tagged FL WT TDP-43 (red).
Fig. 1. Seeded aggregation of pTDP-43 fromALS brain and spinal cord. A)Westernblotting of Sarkosyl insoluble, urea soluble control andALS patient sampleswhichwere used as pTDP-
43 enriched inocula, labelled using polyclonal anti-pTDP-43 (pS409/410) antibody. B) Western blotting of Sarkosyl insoluble (SI) fractions of HEK cells either without plasmid or
expressing the FL WT TDP-43 plasmid. The cells received either no inocula or 5 μg of normal control (NC), parkinson's disease control (PDC) or ALS inocula from motor cortex (MC),
temporal cortex (TCX), or spinal cord (SC). Western blots labelled using anti-FLAG and anti-pTDP-43 antibodies. The graph shows the densitometry of pTDP-43 46 kDa band from SI
fractions of cells expressing WT TDP-43 treated with control or ALS inocula (n = 3 and **p b 0.01) C) Sarkosyl insoluble (SI) fractions of HEK cells transfected with the FL WT TDP-43
plus 5 μg of ALS inocula from ALS MC at 1, 2 and 3 days post inoculation and western blotted using monoclonal anti-FLAG and polyclonal anti-pTDP-43 antibodies. The pTDP-43 bands
are indicated with arrows, and quantiﬁcation was performed on the 46 kDa band using densitometry from n = 5. D) Quantiﬁcation of endogenous TDP-43 levels from SS and SI
fractions of HEK cells expressing no construct (blue) and expressing the FL WT construct (red). Blots are labelled with polyclonal TDP-43 and β-actin of cells either without TDP-43
plasmid (−) or expressing the TDP-43 plasmid (+), and are representative of n= 3. E) Immunoﬂuoresence (IF) staining of HEK cells transfected with 5 μg control or ALS pTDP-43 MC
and SC enriched inocula with the FL WT plasmid. Scale bars = 44 μm, NC = normal control, MC = motor cortex, TCX = temporal cortex, PDC = Parkinson's disease control, SS =
sarkosyl soluble, SI = sarkosyl insoluble, FL WT = full length wild type TDP-43 plasmid. All blots and IF images are representative images of n = 3. All western blots were loaded with
equal amounts of protein in eachwell per gel. Error bars represent SEM. Statistical signiﬁcancewas calculated using an unpaired two tailed students t-testwhere **p b 0.01 and ***p b 0.001.
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non-neuronal cell type here may not provide a suitable architecture for
the propagation process. As an additional method of exploring pTDP-43
aggregate propagation we also attempted to use conditioned media
from cells treated with ALS seeds and incubate this conditioned media
on fresh naïve cells for 3 days. In this case we were unable to observe
the formation of any pTDP-43 inclusions in cells treated with the condi-
tioned media.
3.5. TDP-43 seeding and toxicity in motor neuron-like cell line
In order to build a more relevant cellular model of TDP-43 seeded
aggregation and toxicity, we replicated our original seeding experi-
ments in a mouse motor neuron-like cell line. This cell line is a hybrid-
oma fusion of mouse embryonic motor neuron enriched cells with
mouse neuroblastoma cells producing the neuroblastoma spinal cord
cell line (NSC-34). These cells are immortalized motor neurons that ex-
press many physiological characteristics of primary motor neurons
(Cashman et al., 1992). In addition, they can also be differentiated to
develop into mature cholinergic motor neurons as a useful model of
motor neuron degeneration (Maier et al., 2013). Using this cell line,
we next demonstrated that TDP-43 can be seeded directly from ALS
CNS tissue extracts. We demonstrated that both ALS brain and spinal
cord extracts can induce the formation of pTDP-43 bands at ~46 kDa
and ~25 kDa after co transfection of the cells with the TDP-43 plasmid
at 3 days (Fig. 5A). This was also demonstrated with pTDP-43 immuno-
ﬂuorescence staining of the NSC-34 cells whereby the only inclusions
detected were in cells inoculated with the TDP-43 plasmid and the
ALS brain or spinal cord extracts compared to cells transfected with
the TDP-43 plasmid and control (Fig. 5C).
Next, to determine if the pTDP-43 aggregates were toxic to these
cells, we performed a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay to assess cellular viability. We treated
the NSC-34 cells with a control spinal cord sample (NC SC) and separate
CNS regions that we had previously demonstrated signiﬁcant seeding
capacity, which were the ALS brain (TCX) and spinal cord (SC) samples.
The MTT assay revealed no reduction in cell viability in cells treated
Fig. 3. Serial passage of pTDP-43 aggregates to naïve cells expressing TDP-43. HEK cells containing aggregates that were co-transfected with full length wild type TDP-43 plasmid (FL
WT) and ALS TCXwere extracted in sarkosyl and the insoluble fractionwas inoculated into naïve cells expressing FLWT TDP-43 in order to passage the seeding reaction.Western blot (A)
and immunoﬂuorescence (B) demonstrates the formation of pTDP-43 bands and aggregates with the FL WT + ALS TCX, and then stronger bands and aggregates in the FL WT + SK
(insoluble fraction of HEK cells containing aggregates) after 3 days. Diagram (C) shows the increased amount of pTDP-43 46 kDa bands quantiﬁed by densitometry in passaged cells
compared to cells exposed to initial ALS TCX extract, and corrected for FLAG expression. D) Densitometry of pTDP-43 46 and 25 kDa bands corrected for using β-actin in the initial
inocula and the ﬁrst and second passage of the cells. Error bars represent mean ± SEM where n = 3 and signiﬁcance was determined using an unpaired two tailed students t-test
(*p b 0.05, **p b 0.01,***p b 0.001).
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with the ALSbrain and spinal cord extracts alone in comparison the con-
trol brain extract (Fig. 5B). However, cells expressing the TDP-43 plas-
mid and then treated with the ALS brain and spinal cord extracts,
demonstrated signiﬁcant reduction in cellular viability with brain
(*p b 0.05) and spinal cord (**p b 0.01) compared to cells treated with
TDP-43 plasmid alone and TDP-43 plasmid plus control (Fig. 5B). This
would suggest that the reduced cell viability observed is due either to
toxic effects of the aggregated TDP-43 or accelerated loss of normal
function of TDP-43 in the seeded cells, or both.
Increasing evidence now implicates oligomeric species of aggre-
gated proteins as the neurotoxic component in a number of neurode-
generative diseases (Colla et al., 2012; Fá et al., 2016; Fang et al.,
2014; Lasagna-Reeves et al., 2011; Tian et al., 2013; Usenovic et al.,
2015; Ward et al., 2012; Wilcox et al., 2011; Winner et al., 2011).
Indeed, more recent evidence demonstrates the presence of toxic
TDP-43 oligomers in patients with FTLD and ALS (Fang et al., 2014;
Kao et al., 2015). To further demonstrate one of the potential causes
of this observed reduced cell viability we wanted to determine the
presence of these oligomers in our cell model. In order to do this
we used a polyclonal TDP-43 oligomer (TDP-O) antibody developed
by Dr. Yun-Ru Chen and colleagues (Fang et al., 2014). We used this
TDP-O antibody to stain for TDP-43 oligomers in our cells treated
with the TDP-43 plasmid plus a control or ALS brain and spinal
cord tissue. We demonstrate the presence of the type of spherical
TDP-43 oligomers detected by Fang and colleagues, which co-local-
ise with FLAG present only in cells treated with FL WT TDP-43 plus
ALS brain or spinal cord samples but not in control treated cells
(Fig. 5D).
Fig. 4. pTDP-43 aggregate spread to naïve cells expressing GFP. Co-culture of cells containing pTDP-43 aggregates and cells expressing GFP in a 1:1 ratio. After 3 days of incubation the
cells were stained with pS409/410 (pTDP-43) (red) and DAPI (blue). Images (A) and (B) are 3D reconstructions of cells with pTDP-43 aggregates (Red). The red lines represent the X-Y
axis, the green line represents the X-Z axes and blue line represents the Y-Z axes. Images (C) and (D) are intensity distribution proﬁles of images (A) and (B) respectively, with blue lines
representing DAPI, green lines representing GFP and red line representing pTDP-43 in a merged image. All images are representative of 3 independent experiments.
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4. Discussion
Developing cellular models of TDP-43 protein aggregation has been
the focus of many studies in order to understand the protein aggrega-
tion process and themolecularmechanisms underlying the disease pro-
cess in ALS or FTLD (Dewey et al., 2012). To date studies have largely
utilised the overexpression of mutant, expanded, deleted or truncated
constructs and chemical modiﬁcation to induce the aggregation of
TDP-43 (Johnson et al., 2009; Nonaka et al., 2009a, 2009b; van Eersel
et al., 2011; Wang et al., 2013). Whilst ALS brain tissue has been previ-
ously seeded (Nonaka et al., 2013), we have developed a TDP-43 aggre-
gation model that can be reproduced directly from pTDP-43 extracts
from both the brain and spinal cord of patients with ALS, the latter, ar-
guably being the more relevant pathological tissue in ALS, and which
has not been previously demonstrated. We have also shown that only
CNS samples demonstrating pTDP-43 on western blotting are capable
of being transmitted to our cell system. Previous models demonstrated
the seeding of TDP-43 from recombinant protein which was not phos-
phorylated. This discrepancy may be due to the fact that TDP-43 is
very prone to aggregate in vitro (Johnson et al., 2009), and recombinant
protein aggregates may not represent the TDP-43 aggregated species
found in ALS pathological tissue.
We have demonstrated that ALS spinal cord extracts form less of the
25 kDa C-terminal fragments on western blotting of the seeded cell ex-
tracts, compared with seeding from brain tissue and recapitulates the
distribution observed in ALS patients (Igaz et al., 2008). Indeed, if
these C-terminal fragments are more prone to develop in the brain, it
would suggest that the cleavage product may not be as important for
Fig. 5. TDP-43 seeding, toxicity and oligomer formation in amotor neuron like (NSC-34) cell line.A)Western blot showing the formation of pTDP-43 46 and 25 kDa bands only when
both the FLWT and ALS TCX and SC samples are transfected and not present in cells transfectedwith the ALS TCX or SC samples alone. B)MTT assay measuring NSC-34 cell viability after
inoculationwith control and ALS samples± the FLWT TDP-43 plasmid showing signiﬁcantly reduced cell viability only in cells inoculatedwith the plasmid and ALS samples compared to
all other treatments. Error bars representmean±SEMwith three repeats, and analysiswas conducted by a oneway ANOVAwith a post hoc Tukey test to compare all groups. **p b 0.01 and
***p b 0.001. C)Representative images of the formation of pTDP-43 aggregates (green) in theNSC-34 cell line treatedwith ALS TCX and SC sampleswhich are not present in control treated
cells. All scale bars =35 μm. D) Representative images of TDP-43 oligomers (TDP-O) (green) present in cells seeded with ALS samples and not controls.
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toxicity, as cell death is much more prominent in the spinal cord com-
pared to brain in ALS patients. From our time course experiments we
also demonstrate that the cleavage of TDP-43, which results in the for-
mation of the 25 kDa pTDP-43 fragments, occurs post-phosphorylation
of the full length protein and that phosphorylation is an earlier event in
ALS pathogenesis.
Whilst we required overexpression of normal TDP43 in order to
demonstrate transmission, we did not see spontaneous generation of
pathological TDP-43 in cells not seeded with ALS tissue, supporting
that TDP-43 aggregation was exclusively as a result of cell seeding.
This further supports the prion-like nature of TDP-43, with the require-
ment of a sufﬁcient substrate and seed, as observed when modelling
prion disease (Prusiner et al., 1990; Tamgüney et al., 2006).
Our next observation was the novel demonstration of a diverse
range of aggregated pTDP-43 morphologies recapitulating those seen
in post-mortem ALS CNS tissue. TDP-43 inclusions take on the form of
either skein, dash, round, dot or granular ‘pre-inclusions’ (Mori et al.,
2008). The presence of ‘pre-inclusions’ in our cell model indicate that
some pTDP-43 aggregates are still immature, suggesting that with lon-
ger incubation periods they will mature into larger inclusions. It is
thought that ﬁne pTDP-43 positive ﬁlaments and wisp inclusions even-
tually mature into coarse thick skein inclusions, and round inclusions
arise from the maturation of punctate granules (Mori et al., 2008).
Prion strains can be serially passaged and propagated in vitro and in
vivo to next generations of animals or naïve cells where they replicate
the same conformational protein structure (Collinge and Clarke,
2007). This is important because, if prion-like mechanisms do underlie
disease pathogenesis in ALS, then stable strains or ‘clouds’ of TDP-43 as-
semblies may be responsible for the varied clinical presentation in ALS
and stereotypical network spread of pathology. We were able to dem-
onstrate the passage of pTDP-43 pathology to FLWT TDP-43 expressing
naïve cells by extracting and utilizing the insoluble fraction of the ALS
tissue seeded cells, containing pTDP-43 aggregates. On serial passage
there was an increase in the quantity of pTDP-43 46 kDa bands on a
western blot (***p b 0.001) suggesting that this seeding process is accel-
erated upon passaging. The increased accumulation of aggregated TDP-
43 on serial passagemay suggestmore efﬁcient propagation on passage
and raises the possibility of the existence of strains of pathological TDP-
43; a phenomena ﬁrst demonstrated in the prion diseases, but more re-
cently also demonstrated with alpha synuclein (Bousset et al., 2013;
Guo et al., 2013; Peelaerts et al., 2015) and Tau (Sanders et al., 2014).
Whilst the increase in pTDP-43 fractions upon serial passage may sim-
ply represent an enrichment of seeding material in the second cycle of
inoculation, comparing the total amount of pTDP-43 across all inoculas
would suggest that our ﬁndings may represent an increase in efﬁciency
of seeded propagation through selection of more efﬁcient seeding spe-
cies/assemblies. Future investigationwill shed further light on this mat-
ter and will include the effects of further serial passaging of pTDP-43.
Next,we investigatedwhether pTDP-43 aggregates could spread from
cell to cell in a prion-like manner and has previously been reported
(Nonaka et al., 2013). After co-culturing cells containing pTDP-43 aggre-
gateswith ‘acceptor’ cells expressing GFP in a 1:1 ratio for 3 days, numer-
ous aggregates were formed, and a small number of cells expressing GFP,
demonstrated cytoplasmic pTDP-43 aggregates, suggesting that these ag-
gregates are indeed spreading to new cells. Longer co-culture incubation
periods with stable GFP expressing cell lines may result in more effective
propagation. However, from our results, it does suggest that the pTDP-43
aggregates do spread from cell to cell in a prion-likemanner. The fact that
we did not observe propagation with conditioned media could be due to
the short incubation times, negligible pTDP-43 aggregates secreted into
the conditioned media, or aggregate instability. Alternatively, the cells
may require close contact for signalling mechanisms required for aggre-
gate spread/uptake. Whilst these experimental data demonstrate uptake
of aggregates from one cell to another, rather than de novo aggregation
in the receptor cells, they support the non-cell autonomous spread of
ALS pathology (Ilieva et al., 2009).
The presence of TDP-43 in the exosomal fractions of TDP-43 ex-
pressing cells treated with the ALS extract has been previously demon-
strated which suggests that TDP-43 pathology is propagated at least
partly via exosomes (Nonaka et al., 2013). Indeed, other ﬁndings from
cerebrospinal ﬂuid suggest that TDP-43 aggregates may spread via
exosomes and tunnelling nanotubules (Ding et al., 2015). Additionally,
recent studies utilizing staging of pTDP-43 pathology in the brain
(Brettschneider et al., 2013) and spinal cord (Brettschneider et al.,
2014) suggest that pTDP-43 pathology may propagate transynaptically
in an anterograde fashion along corticofugal axonal projections (Braak
et al., 2013). Indeed, this is supported by data from the same group
showing signiﬁcant diffusion tensor imaging (DTI) changes along the
selected regions originally measured from the pathological staging
(Kassubek et al., 2014). The collective data here supports our ﬁndings
of a cell to cell spreading of pTDP-43 pathology.
The exact cellular mechanisms for pathological TDP-43 spread still
remain elusive. Aside from exosome propagation of pTDP-43, other
mechanisms of potential aggregate spread include free ﬂoating aggre-
gates or seeds or nanotubule transmission as seen previously with
prions (Gousset et al., 2009) and now recently observed with TDP-43
(Ding et al., 2015). Additionally, themethod of seed uptake by the recip-
ient cell has yet to be discovered. These potential methods of uptake
could include direct penetration of the plasma membrane, ﬂuid phase
endocytosis, or receptor-mediated endocytosis. Indeed, SOD1 has re-
cently been shown to propagate via exosomes and free ﬂoating aggre-
gates and seeds which are taken up by lipid raft macropinocytosis
(Grad et al., 2014; Münch et al., 2011). Uptake of TDP-43 could also po-
tentially occur via various other protein dependent uptake mechanisms
such as clathrin, caveolin and dynamin-mediated endocytosis. Our cell
model of aggregation will allow investigation of the exact mechanisms
of this propagation and may provide essential clues as to how to target
these mechanisms in an attempt to therapeutically arrest TDP-43
propagation.
In order to determine the effects of TDP-43 seeding and aggregation
from ALS CNS extracts within a neuronal cell line, we replicated this
seeding reaction in the mouse motor neuron-like cell line (NSC-34).
We report the successful demonstration of TDP-43 pathology in the
NSC-34 cell line expressing the TDP-43 plasmid and following exposure
to ALS CNS extract. We also demonstrate that TDP-43 seeding can de-
crease the viability of these NSC-34 cells. As this decrease in cellular vi-
ability only occurs with the TDP-43 plasmid and ALS CNS extract
exposure, it is highly probable that TDP-43 is the responsible species.
It is still unclear if or how protein misfolding and aggregation is toxic
to cells. One hypothesis is the formation of oligomeric aggregation inter-
mediates. A number of neurodegenerative disease related proteins now
demonstrate that the oligomeric species ofmisfolded aggregated proteins
may be responsible for neurodegeneration in a number of disorders (Tian
et al., 2013; Wilcox et al., 2011; Winner et al., 2011). Indeed, recent ﬁnd-
ings nowsuggest that TDP-43 oligomersmay also be the toxic component
present in patients with FTLD (Fang et al., 2014). Here we demonstrate
that TDP-43 seeding in the NSC-34 cell line can develop spherical annular
TDP-43 oligomers as reported by Fang and colleagues, raising thepossibil-
ity that these species may also be responsible for the observed TDP-43
mediated reduction in cell viability.
5. Conclusion
Our ﬁndings here demonstrate that TDP-43 can seed the formation
of TDP-43 aggregates in vitro directly from both ALS brain and spinal
cord extracts. The morphology of the pathological TDP-43 inclusions is
highly reminiscent of the TDP-43 pathology seen in the ALS patients,
and all different morphologies of inclusions can be observed. We have
also demonstrated that TDP-43 can propagate from cell to cell in co-cul-
ture experiments and can be serially passaged from cell extracts con-
taining pTDP-43 aggregates. The increased accumulation of
aggregated TDP-43 on serial passage may suggest more efﬁcient
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propagation, and raises the possibility of the existence of strains of path-
ological TDP-43. Finally, we are able to induce this TDP-43 pathology in
a pathologically relevant motor neuron-like cell line (NSC-34) and
demonstrate decreased cellular viability and the formation of oligomer-
ic species of TDP-43. These data further support the prion-like nature of
TDP-43, conﬁrming and extending accumulating evidence for the prop-
agative nature of ALS. Indeed, our experimental paradigm could be used
in in vitro assays to explore these prion-like mechanisms further and to
screen for therapies to inhibit TDP-43 seeding, propagation and toxicity
in order to potentially ameliorate this devastating condition.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2016.08.007.
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